45
Participants
Start Date
June 25, 2021
Primary Completion Date
June 30, 2023
Study Completion Date
December 31, 2024
TQ05105 Tablet
TQ05105 tablet is a Janus Kinase (JAK) inhibitor, which can inhibit the abnormal activation of JAK 2-V617F mutation, thereby inhibiting the sustained abnormal activation of JAK / STAT pathway.
The First Affiliated Hospital of Soochow University, Suzhou
The First Affiliated Hospital of USTC (Anhui Provincial Hospital), Hefei
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin
The First Affiliated Hospital, Zhejiang University School of Medicine, Hanzhou
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan
Tongji Hospital Tongji Medical College of HUST, Wuhan
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Zhujiang Hospital of Southern Medical University, Guangzhou
Nanfang Hospital of Southern Medical University, Guangzhou
Guangzhou First People's Hospital, Guangzhou
The First Affiliated Hospital of Guangxi Medical University, Nanning
The Second Hospital of Hebei Medical University, Shijiazhuang
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY